Mo1746 DYE-BASED CHROMOENDOSCOPY VERSUS STANDARD-DEFINITION AND HIGH-DEFINITION WHITE LIGHT ENDOSCOPY FOR ENDOSCOPIC ADENOMA DETECTION IN LYNCH SYNDROME: META-ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED TRIALS

2020 ◽  
Vol 91 (6) ◽  
pp. AB479
Author(s):  
Britt B. Houwen ◽  
Nahid Mostafavi ◽  
Jasper Vleugels ◽  
Robert Hüneburg ◽  
Christof Lamberti ◽  
...  
2018 ◽  
Vol 154 (6) ◽  
pp. S-371
Author(s):  
Ramprasad Jegadeesan ◽  
Madhav Desai ◽  
Tharani Sundararajan ◽  
Venkata Subhash Gorrepati ◽  
Viveksandeep Thogulva Chandrasekar ◽  
...  

Haematologica ◽  
2013 ◽  
Vol 98 (6) ◽  
pp. 980-987 ◽  
Author(s):  
S. Bringhen ◽  
M. V. Mateos ◽  
S. Zweegman ◽  
A. Larocca ◽  
A. P. Falcone ◽  
...  

2016 ◽  
Vol 194 (6) ◽  
pp. 681-691 ◽  
Author(s):  
Jason A. Roberts ◽  
Mohd-Hafiz Abdul-Aziz ◽  
Joshua S. Davis ◽  
Joel M. Dulhunty ◽  
Menino O. Cotta ◽  
...  

2008 ◽  
Vol 26 (35) ◽  
pp. 5802-5812 ◽  

BackgroundAfter a 1999 National Cancer Institute (NCI) clinical alert was issued, chemoradiotherapy has become widely used in treating women with cervical cancer. Two subsequent systematic reviews found that interpretation of the benefits was complicated, and some important clinical questions were unanswered.Patients and MethodsWe initiated a meta-analysis seeking updated individual patient data from all randomized trials to assess the effect of chemoradiotherapy on all outcomes. We prespecified analyses to investigate whether the effect of chemoradiotherapy differed by trial or patient characteristics.ResultsOn the basis of 13 trials that compared chemoradiotherapy versus the same radiotherapy, there was a 6% improvement in 5-year survival with chemoradiotherapy (hazard ratio [HR] = 0.81, P < .001). A larger survival benefit was seen for the two trials in which chemotherapy was administered after chemoradiotherapy. There was a significant survival benefit for both the group of trials that used platinum-based (HR = 0.83, P = .017) and non–platinum-based (HR = 0.77, P = .009) chemoradiotherapy, but no evidence of a difference in the size of the benefit by radiotherapy or chemotherapy dose or scheduling was seen. Chemoradiotherapy also reduced local and distant recurrence and progression and improved disease-free survival. There was a suggestion of a difference in the size of the survival benefit with tumor stage, but not across other patient subgroups. Acute hematologic and GI toxicity was increased with chemoradiotherapy, but data were too sparse for an analysis of late toxicity.ConclusionThese results endorse the recommendations of the NCI alert, but also demonstrate their applicability to all women and a benefit of non–platinum-based chemoradiotherapy. Furthermore, although these results suggest an additional benefit from adjuvant chemotherapy, this requires testing in randomized trials.


Sign in / Sign up

Export Citation Format

Share Document